Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study

被引：0

作者：

Munir, Talha ^{[1
]}

Rawstron, Andrew ^{[2
]}

Brock, Kristian ^{[3
]}

Munoz-Vicente, Samuel ^{[3
]}

Yates, Francesca ^{[3
]}

Bishop, Rebecca ^{[3
]}

MacDonald, Donald ^{[4
]}

Fegan, Christopher ^{[5
]}

McCaig, Alison ^{[6
]}

Schuh, Anna ^{[7
]}

Pettitt, Andrew ^{[8
]}

Gribben, John ^{[9
]}

Patten, Piers ^{[10
]}

Devereux, Stephen ^{[11
]}

Bloor, Adrian ^{[12
]}

Fox, Christopher ^{[13
]}

Forconi, Francesco ^{[14
]}

Hillmen, Peter ^{[14
]}

机构：

[1] St James Univ Hosp, Leeds, W Yorkshire, England

[2] Leeds Teaching Hosp NHS Trust, HMDS, Leeds, W Yorkshire, England

[3] Univ Birmingham, Birmingham, W Midlands, England

[4] Imperial Coll London, Hammersmith Hosp, London, England

[5] Univ Cardiff, Cardiff, S Glam, Wales

[6] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland

[7] Univ Oxford, Oxford, England

[8] Univ Liverpool, Liverpool, Merseyside, England

[9] Barts Canc Inst, London, England

[10] Kings Coll London, London, England

[11] Kings Coll Hosp London, London, England

[12] Univ Manchester, Manchester, Lancs, England

[13] Nottingham Univ Hosp NHS Trust, Nottingham, England

[14] St James Univ, Leeds Teaching Hosp, Leeds, W Yorkshire, England

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2143

引用

页码：227 / 228

页数：2